Pegvaliase: Difference between revisions
Content deleted Content added
Anypodetos (talk | contribs) New ATC code; navbox; stub sorting |
first-in-class; add link and portal |
||
| Line 59: | Line 59: | ||
'''Pegvaliase''' (trade name '''Palynziq''') is a medication for the treatment of the genetic disease [[phenylketonuria]].<ref name=FDA2018Sub/> Chemically, it is a [[pegylated]] [[derivative (chemistry)|derivative]] of the enzyme [[phenylalanine ammonia-lyase]] that metabolizes [[phenylalanine]] to reduce its blood levels.<ref>{{Cite web | url = https://www.palynziq.com/hcp/ | title = Palynziq | publisher = BioMarin Pharmaceutica}}</ref> |
'''Pegvaliase''' (trade name '''Palynziq''') is a medication for the treatment of the genetic disease [[phenylketonuria]].<ref name=FDA2018Sub/> Chemically, it is a [[pegylated]] [[derivative (chemistry)|derivative]] of the enzyme [[phenylalanine ammonia-lyase]] that metabolizes [[phenylalanine]] to reduce its blood levels.<ref>{{Cite web | url = https://www.palynziq.com/hcp/ | title = Palynziq | publisher = BioMarin Pharmaceutica}}</ref> |
||
It was approved by the [[Food and Drug Administration]] for use in the United States in 2018.<ref name=FDA2018Sub>{{cite web | url = https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm608835.htm | title = FDA approves a new treatment for PKU, a rare and serious genetic disease | publisher = [[Food and Drug Administration]] | date = May 24, 2018}}</ref> |
It was approved by the [[Food and Drug Administration]] for use in the United States in 2018.<ref name=FDA2018Sub>{{cite web | url = https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm608835.htm | title = FDA approves a new treatment for PKU, a rare and serious genetic disease | publisher = [[Food and Drug Administration]] | date = May 24, 2018}}</ref> The U.S. [[Food and Drug Administration]] (FDA) considers it to be a first-in-class medication.<ref>{{cite report | title=New Drug Therapy Approvals 2018 | website=U.S. [[Food and Drug Administration]] (FDA) | date=January 2019 | url=https://www.fda.gov/media/120357/download | format=PDF | access-date=16 September 2020}}</ref> |
||
==References== |
==References== |
||
{{reflist}} |
{{reflist}} |
||
== External links == |
|||
* {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/name/pegvaliase | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Pegvaliase }} |
|||
{{Other alimentary tract and metabolism products}} |
{{Other alimentary tract and metabolism products}} |
||
{{Portal bar | Medicine}} |
|||
[[Category:Drugs acting on the gastrointestinal system and metabolism]] |
[[Category:Drugs acting on the gastrointestinal system and metabolism]] |
||
[[Category:Recombinant proteins]] |
[[Category:Recombinant proteins]] |
||
{{gastrointestinal-drug-stub}} |
{{gastrointestinal-drug-stub}} |
||
Revision as of 06:42, 17 September 2020
| Clinical data | |
|---|---|
| Trade names | Palynziq |
| Other names | Pegvaliase-pqpz; PEG-PAL; RAvPAL-PEG |
| Routes of administration | Subcutaneous injection |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| 3D model (JSmol) | |
| |
| |
Pegvaliase (trade name Palynziq) is a medication for the treatment of the genetic disease phenylketonuria.[2] Chemically, it is a pegylated derivative of the enzyme phenylalanine ammonia-lyase that metabolizes phenylalanine to reduce its blood levels.[3]
It was approved by the Food and Drug Administration for use in the United States in 2018.[2] The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[4]
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ a b "FDA approves a new treatment for PKU, a rare and serious genetic disease". Food and Drug Administration. May 24, 2018.
- ^ "Palynziq". BioMarin Pharmaceutica.
- ^ New Drug Therapy Approvals 2018 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2019. Retrieved 16 September 2020.
External links
- "Pegvaliase". Drug Information Portal. U.S. National Library of Medicine.
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |